Pharmacy Essentials for HCV Screening and Management
  • CME

This CME/CPE-certified activity provides a comprehensive overview of HCV service provision from screening recommendations to treatment administration and monitoring, with a primary focus on the role of pharmacists in expanding HCV screening and improving other services for individuals with or at risk for HCV infection.

John Faragon, PharmD, BCPS, AAHIVP
Program Director
Aileen Chi, PharmD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: January 11, 2019 Expiration: January 10, 2020
Multimedia Pharmacy Essentials for HCV Screening and Management
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
HCV Epidemiology, Risk Factors, and Testing Recommendations
Review the current status of the HCV epidemic in the United States and which risk factors guide HCV testing recommendations
Launch HCV Epidemiology, Risk Factors, and Testing Recommendations
Linkage to HCV Care and Pretreatment Considerations
Consider the important role pharmacists can play in linking patients to HCV care and learn what is involved in the pretreatment workup
Launch Linkage to HCV Care and Pretreatment Considerations
HCV Treatment Options
Find out key features of currently recommended HCV regimens, including dosing recommendations, pharmacologic characteristics, selected drug-drug interactions, and the most common adverse events
Launch HCV Treatment Options
HCV Treatment and Insurance Coverage
Learn the nuances and challenges involved in navigating HCV treatment access for patients, including the prior authorization process, medication claim review entities, and available resources for assisting patients
Launch HCV Treatment and Insurance Coverage
HCV Medication Counseling
Review the critical role of pharmacists in educating patients on how to take their HCV treatment regimens, important drug-drug interactions with other commonly used medications, and how to manage any adverse events they may experience
Launch HCV Medication Counseling
Preventing HCV Reinfection
Gain an understanding of how pharmacists can counsel patients at risk of HCV reinfection on how to reduce that risk and the need for continued screening if they remain at risk
Launch Preventing HCV Reinfection

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply expert guidelines in identifying appropriate individuals for HCV screening and best practices for linkage to HCV care
  • Provide appropriate patient counsel about HCV treatment and prevention strategies in the pharmacy setting
  • Implement pharmacy-based strategies to support HCV therapy provision, including prescribing and/or dispensing, drug-drug interaction assessment, and on-therapy monitoring

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

John Faragon, PharmD, BCPS, AAHIVP

Pharmacist, HIV and HCV Medicine
Albany Medical Center
Regional Pharmacy Director
Northeast/Caribbean AIDS Education and Training Center (AETC)
Albany, New York

John Faragon, PharmD, BCPS, AAHIVP, has disclosed that he has received fees for non-CME/CE services from AbbVie, Gilead Sciences, Janssen, and Merck.

Faculty

Aileen Chi, PharmD

Transplant/Hepatitis C Clinical Pharmacist
UCSF Medical Center
San Francisco, California

Aileen Chi, PharmD, has no real or apparent conflicts of interest to report.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Ashley Bohn, PhD, MS, RVT

Clinical Editor

Ashley Bohn, PhD, MS, RVT, has disclosed that she has received fees for non-CME activities from Lilly and Merck.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for US pharmacists and other healthcare providers who care for patients with or at risk of HIV and HCV infection.

Goal

The goal of this activity is to improve pharmacists’ competence in contributing to the prevention and management of HIV and HCV infection.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-0000-19-001-H02-P. This program is designated for up to 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit.

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 11, 2019, through January 10, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

HIV slides on innovative ART, including two-drug ART and long-acting injectable ART. From Clinical Care Options Symposium at IAS 2019

Andrea Mantsios, PhD Anthony M. Mills, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD person default Omar Sued, MD, PhD Babafemi Taiwo, MBBS Released: July 19, 2019

Karine Lacombe, MD, PhD, commentary on results from 2 randomized trials evaulating INSTI initation during pregnancy from CROI 2019 and potential implications for HIV care in France

Karine Lacombe, MD, PhD Released: July 18, 2019

Preview of IAS 2019 data from Mexico; phase III BRIGHTE, ADVANCE, GEMINI, TANGO, DISCOVER trials, and prevention and treatment in special populations.

Anton L. Pozniak, MD, FRCP Released: July 16, 2019

Slideset from CCO on HIV perspectives in Europe, challenging case discussions from Chloe Orkin, Juergen Rockstroh, Esteban Martinez.

Released: July 10, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?